QUOTE AND NEWS
Benzinga  Jun 5  Comment 
Palatin Technologies, Inc. (NYSE: PTN) spiked dramatically on Friday in response to Thursday's FDA approval of Sprout Pharmaceuticals' female sexual dysfunction drug, flibanserin. Roth Capital analyst Joe Pantginis published a report on Friday...
TheStreet.com  Jun 5  Comment 
NEW YORK (TheStreet) -- Palatin Technologies shares up 34.52% to $1.21 in trading on Friday after an Food and Drug Administration advisory panel voted 18-6 to approve a drug called flibanserin that treats low libido in women. While Palatin...
Benzinga  Jun 5  Comment 
Palatin Technologies, Inc. (NYSE: PTN) shares jumped 59.34 percent to $1.45 following the Thursday's FDA approval of hypoactive sexual desire disorder treatment for women, flibanserin. JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) shares...
Benzinga  Dec 29  Comment 
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that...
SeekingAlpha  Sep 9  Comment 
By SA Transcripts: Palatin Technologies, Inc. (NYSEMKT:PTN) Q4 2014 Earnings Conference Call September 09, 2014 11:00 AM ET Executives Carl Spana - President and CEO Steve Wills - CFO, COO and EVP Jeffrey Edelson - CMO ...
StreetInsider.com  Jul 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Palatin+Technologies+%28PTN%29+Receives+USPTO+Notice+of+Allowance+for+%27422+Application/9647370.html for the full story.
SeekingAlpha  May 13  Comment 
Palatin Technologies, Inc (PTN) Q3 2014 Earnings Conference Call May 13, 2014 11:00 AM ET Executives Carl Spana - President and CEO Steve Wills - CFO, COO and EVP Dr. Jeffrey Edelson - CMO Analysts Charles Duncan -...




 
TOP CONTRIBUTORS

Palatin Technologies (AMEX:PTN) is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule agonist compounds with a focus on therapeutics that modulate melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases.

Palatin has collaborations with industry leaders AstraZeneca (NYSE:AZN) and the Mallinckrodt division of Covidien (NYSE:COV).

Product Portfolio PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of heart failure, including congestive heart failure. Bremelanotide, a peptide melanocortin receptor agonist, for prevention of organ damage secondary to cardiac surgery and related indications. PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of difficult-to-control hypertension, including dialysis patients with hypertension. PL-6983, a peptide melanocortin-4 receptor agonist, for treatment of female sexual dysfunction. Ongoing research collaboration and global license with AstraZeneca AB on melanocortin receptor-based compounds for treating obesity and related metabolic syndrome. NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection, is the subject of a strategic collaboration agreement with the Mallinckrodt division of Covidien. All ongoing clinical trials and regulatory approvals of NeutroSpec have been suspended while the Company and Mallinckrodt evaluate future development and marketing activities involving NeutroSpec.

Carl Spana, Ph.D., President and Chief Executive Officer Dr. Spana, co-founder of Palatin, has served as president and chief executive officer since 2000. He has been a director of Palatin since 1996 and has been a director of Palatin’s wholly-owned subsidiary, RhoMed Incorporated, since 1995. From 1996 to 2000, Dr. Spana served as an executive vice president and chief technical officer of Palatin.

From 1993 to 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From 1991 to 1993, Dr. Spana was a research associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana is a director of AVAX Technologies, Inc., a publicly traded medical technology company, and a director of Curalogic A/S, a Danish life science company publicly traded on the Copenhagen Stock Exchange.

Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.





References

http://www.palatin.com/aboutpalatin/overview.asp

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki